Viloxazine (Qelbree): A Faster Strattera?

On April 2, 2021, viloxazine, brand name Qelbree, received FDA approval for the treatment of ADHD in children and adolescents ages 6-17 years old. The latest issue of The Carlat Child Psychiatry Report includes a News of Note covering this newly approved medication for ADHD. In this podcast, we discuss the advantages and disadvantages of viloxazine for children and adolescents with ADHD.

https://www.thecarlatreport.com/podcast/viloxazine-qelbree-a-faster-strattera-2/

 

Author
Joshua Feder, M.D. Dr. Feder's Blog

You Might Also Enjoy...

Positive Development on Affect Autism

Positive Development is a start-up aiming to change the culture of the current state of autism treatment so that it opens the door for evidence-based developmental approaches for autism that are much more humane.

Three Approaches to Autism Intervention

We break down three main autism intervention approaches, and provide you with information that will help you improve on your abilities to recognize which particular autism intervention might be best for a specific patient.

Pharmacogenetics: Not Quite Ready for Prime Time?

There's so much marketing for genetic testing, but does it really help clinical care? Listen to our interview with Dr. Aaron Besterman about how genetic tests work, and what can be reliably taken away from them.

Duty to Warn: Antidepressants in Children and Adolescents

For 17 years, since the FDA black box warning about suicidality with antidepressants, our community has quoted data that downplays this concern. We were wrong. We were deceived. Antidepressants can be lifesaving, but there really is a duty to warn.

Affect Autism - Accept Reality?

Returning guest Dr. Joshua Feder and I discuss why it is so important to emphasize that accepting reality is a process that parents need to be supported in, and the ways in which we can do this.